A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants

Completed · Phase 1

Conditions studied: Healthy Volunteers

In brief

This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous administration with an on-body injector relative to a prefilled syringe

Key facts

Study ID

NCT07007091

Run by

AbbVie

People needed

260

Starts

2025-06-12

Expected to finish

2026-01-15

Last updated by the study team

2026-01-27

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Body Mass Index (BMI) is ≥ 18.0 to ≤ 32 kg/m2 after rounding to the tenths decimal at screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
• Body weight between 40 kg and 100 kg, inclusive, at the time of screening.
• A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.

You may not qualify if…

• Previous exposure to any anti-interleukin (IL)-12/23 or anti IL-23 treatment for at least one year prior to screening.
• Intention to perform strenuous exercise within one week prior to administration of study treatment and during the study confinement.

Where it is running

• Cpmi /Id# 276490 — Miami, Florida, United States
• Acpru /Id# 276043 — Grayslake, Illinois, United States
• Ppd - Las Vegas Research Unit /ID# 276565 — Las Vegas, Nevada, United States
• PPD Phase I Clinic /ID# 276525 — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.